Dr. Erik Schwiebert is founding CEO and chief scientific officer of DiscoveryBioMed, Inc. (DBM), a life sciences and biotechnology company in Birmingham, Alabama that is focused on leveraging diseased and healthy human cells as platform technologies for ‘humanized’ drug discovery and lead therapeutic asset profiling. Dr. Schwiebert is a cell biologist, physiologist and pathophysiologist who uses a blend of applied science and basic science for drug discovery projects using bioassays in human cells. DBM has multiple preclinical hit-to-lead/lead compound programs focused on specific disorders such as Parkinson’s disease ad autoimmune and renal diseases, including niche human genetic diseases. DBM also performs human cell culture creation, human cell-based drug discovery, and human cell-based bioassays on lead therapeutic assets as contract research services